Grants & Projects per year
Personal profile
Fingerprint
Dive into the research topics where Naheed Alam is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
-
MK2140-011:A Randomized, Open-Label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP versus PolatuzumabVedotin plus R-CHP in Treatment-naïve Participants with GCB Subtype of Diffus
Alam, N. (PI)
Merck Sharp and Dohme Limited Liability Corporation
06/12/25 → 12/1/34
Project: Research
Research output
- 12 Article
-
Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD
Moon, J. H., Hamad, N., Sohn, S. K., Uhm, J., Alam, N., Gupta, V., Lipton, J. H., Messner, H. A., Seftel, M., Kuruvilla, J. & Kim, D., May 1 2017, In: Annals of Hematology. 96, 5, p. 805-815 11 p.Research output: Contribution to journal › Article › peer-review
12 Scopus citations -
Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation
Mayo, S., Messner, H. A., Rourke, S. B., Howell, D., Victor, J. C., Kuruvilla, J., Lipton, J. H., Gupta, V., Kim, D. D., Piescic, C., Breen, D., Lambie, A., Loach, D., Michelis, F. V., Alam, N., Uhm, J., McGillis, L. & Metcalfe, K., Jun 1 2016, In: Bone Marrow Transplantation. 51, 6, p. 841-847 7 p.Research output: Contribution to journal › Article › peer-review
Open Access37 Scopus citations -
Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission
Michelis, F. V., Atenafu, E. G., Gupta, V., Kim, D. D., Kuruvilla, J., Lipton, J. H., Loach, D., Seftel, M. D., Uhm, J., Alam, N., Lambie, A., McGillis, L. & Messner, H. A., Jul 3 2015, In: Bone Marrow Transplantation. 50, 7, p. 907-913 7 p.Research output: Contribution to journal › Article › peer-review
31 Scopus citations -
Modified EBMT pretransplant risk score can identify favorable-risk patients undergoing allogeneic hematopoietic cell transplantation for AML, not identified by the HCT-CI score
Michelis, F. V., Messner, H. A., Uhm, J., Alam, N., Lambie, A., Mcgillis, L., Seftel, M. D., Gupta, V., Kuruvilla, J., Lipton, J. H. & Kim, D., May 1 2015, In: Clinical Lymphoma, Myeloma and Leukemia. 15, 5, p. e73-e81 514.Research output: Contribution to journal › Article › peer-review
11 Scopus citations -
Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation
Alam, N., Atenafu, E. G., Kuruvilla, J., Uhm, J., Lipton, J. H., Messner, H. A., Kim, D. H., Seftel, M. & Gupta, V., Sep 4 2015, In: Bone Marrow Transplantation. 50, 9, p. 1180-1186 7 p.Research output: Contribution to journal › Article › peer-review
21 Scopus citations